MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.93
+0.24
+1.36%
After Hours: 17.93 0 0.00% 16:00 11/11 EST
OPEN
17.65
PREV CLOSE
17.69
HIGH
18.12
LOW
17.59
VOLUME
474.13K
TURNOVER
--
52 WEEK HIGH
18.39
52 WEEK LOW
9.31
MARKET CAP
1.23B
P/E (TTM)
-13.0590
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DRNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

DRNA News

  • Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.1d ago
  • Edited Transcript of DRNA earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.2d ago
  • Dicerna Pharmaceuticals Inc (DRNA) Q3 2019 Earnings Call Transcript
  • MotleyFool.com.3d ago
  • Mixed shelf roundup - healthcare
  • seekingalpha.3d ago

More

Industry

Biotechnology & Medical Research
-0.51%
Pharmaceuticals & Medical Research
-0.43%

Hot Stocks

Name
Price
%Change

About DRNA

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
More

Webull offers Dicerna Pharmaceuticals Inc (DRNA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.